Moxie Dwight's most recent trade in Revance Therapeutics Inc was a trade of 5,979 Common Stock done . Disclosure was reported to the exchange on Feb. 3, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Revance Therapeutics Inc
|
Dwight Moxie | CLO & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 5,979 | 143,794 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | CLO & GC | Sale of securities on an exchange or to another person at price $ 5.04 per share. | 15 Mar 2024 | 8,125 | 137,815 (0%) | 0% | 5.0 | 40,971 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | CLO & GC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.30 per share. | 15 Mar 2024 | 3,269 | 145,940 (0%) | 0% | 5.3 | 17,342 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | CLO & GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 15,143 | 149,209 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Moxie Dwight | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 135,000 | 135,000 | - | - | Performance Stock Units | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 90,000 | 134,066 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 19,346 | 88,511 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.91 per share. | 11 Aug 2023 | 9,592 | 78,919 (0%) | 0% | 18.9 | 181,385 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.65 per share. | 15 Mar 2023 | 7,330 | 48,217 (0%) | 0% | 30.7 | 224,665 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 43,774 | 43,774 | - | - | Employee Stock Option (Right to Buy) | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2022 | 42,349 | 74,043 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 22 Sep 2022 | 18,496 | 55,547 (0%) | 0% | 31.6 | 584,220 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Sale of securities on an exchange or to another person at price $ 27.07 per share. | 14 Sep 2022 | 11,000 | 31,694 (0%) | 0% | 27.1 | 297,798 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.79 per share. | 15 Mar 2022 | 2,881 | 44,923 (0%) | 0% | 15.8 | 45,491 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.79 per share. | 15 Mar 2022 | 2,229 | 42,694 (0%) | 0% | 15.8 | 35,196 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 42,349 | 90,566 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Sale of securities on an exchange or to another person at price $ 34.55 per share. | 02 Feb 2022 | 21,401 | 69,165 (0%) | 0% | 34.5 | 739,338 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 27 Sep 2021 | 1,675 | 47,804 (0%) | 0% | 30 | 50,250 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.73 per share. | 15 Mar 2021 | 2,881 | 49,479 (0%) | 0% | 27.7 | 79,890 | Common Stock |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 35,002 | 35,002 | - | - | Employee Stock Option (Right to Buy) | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 19,346 | 52,360 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 12,250 | 37,250 (0%) | 0% | 0 | Common Stock | |
Revance Therapeutics Inc
|
Dwight Moxie | SVP, GC & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.14 per share. | 30 Sep 2020 | 4,236 | 33,014 (0%) | 0% | 25.1 | 106,493 | Common Stock |